When will caplyta be generic?

Will generics soon be available?

As of now, the caplyta generic is not yet available, but its patent is set to expire in 2027. The exact release date of the generic version will largely depend on regulatory approvals from health authorities worldwide [1]. Caplyta, also known as cariprazine, is an oral medication for the treatment of schizophrenia and bipolar disorder.

What's behind the patent protection?

Caplyta has been protected by patents filed by its manufacturer, Gedeon Richter [2]. The patent protection has limited the sale of generic cariprazine until the patent expires in 2027.

Why is this happening now?

Caplyta was initially approved by the FDA in 2016, and its generic equivalent is expected to become available soon after the patent expires.

What does this mean for patients?

Generic drugs are typically cheaper than their brand-name counterparts. Once the generic version of Caplyta is available, it is expected to provide a lower-cost alternative for patients, which may help improve access to this medication globally.

The availability of the generic Caplyta is subject to various regulatory and commercial considerations and will depend on several market and regulatory factors. Please note that information is subject to change.

Sources:

[1] DrugPatentWatch.com https://drugs.com/nda/CARIPRAZINE

[2] U.S. Food and Drug Administration

Sources:

[1] DrugPatentWatch.com https://www.drugpatentwatch.com/drug/cariprazine

[2] U.S. Food and Drug Administration https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-nme/names-and-abbreviations-new-molecular-entities-cancer-treatment